ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CPT Concepta Plc

1.98
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Concepta Plc LSE:CPT London Ordinary Share GB00BYZ2R301 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.98 1.90 2.20 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Concepta PLC Change of Broker (7367A)

02/01/2018 12:52pm

UK Regulatory


Concepta (LSE:CPT)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Concepta Charts.

TIDMCPT

RNS Number : 7367A

Concepta PLC

02 January 2018

2 January 2018

Concepta plc

("Concepta" or the "Company")

Change of broker

Concepta plc (AIM: CPT) the UK healthcare company and developer of a proprietary product targeted at the mobile health market with a primary focus on women's fertility, today announces that Beaufort Securities Limited has ceased to act as the Company's joint broker with immediate effect. NOVUM Securities Limited remains as the Company's sole broker.

ENDS

Enquiries:

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

NOVUM Securities Limited (Broker)

Colin Rowbury

+44 (0) 20 7399 9400

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

About Concepta Plc:

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility* in women.

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH and hCG* hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future.

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.GBP600m per annum.

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPUGUBCGUPRGPP

(END) Dow Jones Newswires

January 02, 2018 07:52 ET (12:52 GMT)

1 Year Concepta Chart

1 Year Concepta Chart

1 Month Concepta Chart

1 Month Concepta Chart

Your Recent History

Delayed Upgrade Clock